Impella CP Reduces Escalation Need in STEMI Cardiogenic ShockTrial shows micro-axial flow pump reduces escalation rates

European heart journal. Acute cardiovascular care Published June 30, 2026 Study authors: Schrage Benedikt, Beske Rasmus Paulin, Hassager Christian, Jensen Lisette Okkels, Eiskjær Hans, Mang… PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Impella CP reduced escalation to higher tMCS and prolonged time to escalation in STEMI cardiogenic shock, but escalated patients had high mortality.

This post hoc analysis of a randomized controlled trial evaluated the impact of micro-axial flow pump (Impella CP) on the need for escalation to higher-volume temporary mechanical circulatory support (tMCS) in 355 non-comatose patients with STEMI-related cardiogenic shock.

Patients were randomized to Impella CP plus standard of care or standard of care alone. The escalation rate was lower in the Impella CP group (14% vs 20%; adjusted OR 0.52, 95% CI 0.30-0.91). Median time to escalation was significantly longer with Impella CP (12 h vs 0.7 h; P < 0.001).

Baseline lactate predicted escalation in the standard care arm (OR 1.80, 95% CI 1.14-3.13) but not in the Impella CP arm (OR 0.57, 95% CI 0.29-1.15; interaction P < 0.01). Overall mortality in escalated patients was 71.7% vs 48.1% in non-escalated (P < 0.01). Mortality was highest in escalated standard care patients (80.0%) and lower in escalated Impella CP patients (60.0%), comparable to non-escalated standard care (53.2%).

These findings suggest Impella CP may reduce the need for escalation and identify baseline lactate as a potential risk marker. However, as a post hoc analysis, results are hypothesis-generating and require prospective validation.

Researchers analyzed data from 355 patients experiencing cardiogenic shock caused by an acute heart attack. The study compared two treatment paths: one using a micro-axial flow pump (mAFP) and another following standard care. The goal was to see how these methods affected the need for more intense, high-volume mechanical support systems.

The results showed that patients using the mAFP were less likely to need an escalation to higher volume systems compared to those receiving standard care. Additionally, the time before needing a more intensive treatment was significantly longer in the mAFP group. The study also found that while high lactate levels predicted a need for escalation in standard care, they did not do so in the mAFP group.

It is important to note that this was a post-hoc analysis of an existing trial, which means the findings should be interpreted with caution. While the results suggest that certain pumps may offer more time and stability, patients who eventually required escalation faced higher mortality rates overall. Talk to your doctor about how these specific heart support technologies might apply to individual cases.

What this means for you:

The mAFP pump showed a lower rate of treatment escalation compared to standard care in some heart failure cases.

Common questions

What is the main benefit of using a micro-axial flow pump?

The study found that patients using the mAFP had a lower escalation rate to higher volume systems (14% compared to 20% in the standard care group). It also provided more time before such an escalation was needed, with a median of 12 hours compared to just 0.7 hours in the standard care group.

How does this treatment affect patient survival?

The study noted that patients who required escalation to higher volume systems had a mortality rate of 71.7%. In the standard care arm, those who were escalated had a high mortality rate of 80.0%, while those in the mAFP arm who were escalated had a mortality rate of 60.0%.

What role does lactate play in these treatments?

In the standard care group, higher baseline lactate levels predicted a need for escalation. However, in the mAFP group, higher lactate levels did not show a significant association with the need for escalation, suggesting the pump may provide more stability during treatment.

Study Details

Study typeRct

EvidenceLevel 2

PublishedJun 2026

PMID41607344

View Original Abstract ↓

AIMS: In STEMI-related cardiogenic shock, left ventricular unloading with a micro-axial flow pump (mAFP) improved survival in the Danish German (DanGer) Shock trial, though some patients in both groups required escalation to higher volume temporary mechanical circulatory support systems (tMCS). This study aims to investigate tMCS escalation strategies and outcome in non-comatose patients with STEMI-related cardiogenic shock. METHODS AND RESULTS: In this post hoc analysis of the DanGer Shock trial, patients in both study groups were stratified as escalated vs. not escalated to treatments other than a percutaneously implanted mAFP (Impella CP®). Logistic regression models were fitted to investigate the differential association of baseline markers with the likelihood of an escalation in patients randomized to mAFP vs. standard of care, adjusted for age and country. The 180-day all-cause mortality risk for the four groups was evaluated using the Kaplan-Meier method. Of the 355 patients included in the DanGer Shock trial, 60 underwent tMCS escalation, 25/179 (14%) allocated to the mAFP group, and 35/176 (20%) allocated to the control group (adjusted odds ratio 0.52, 95% confidence interval 0.30-0.91). Median time from randomization to escalation was 12 h (2.7-66.5) in the mAFP arm vs. 0.7 h (IQR: 0.4-2.7) in the standard of care arm (P < 0.001). A higher baseline lactate predicted an escalation in the standard of care arm (odds ratio 1.80, 95% confidence interval 1.14-3.13), but not in the mAFP arm (odds ratio 0.57, 95% confidence interval 0.29-1.15, interaction-P < 0.01). Mortality was significantly higher in patients who underwent tMCS escalation (71.7% vs. 48.1%, P < 0.01) and highest in escalated patients from the standard of care arm (80.0%). Interestingly, those escalated in the mAFP arm had a comparable mortality risk to the non-escalated patients in the standard of care group (60.0% vs. 53.2%). CONCLUSION: In the DanGer Shock trial of STEMI-related cardiogenic shock, escalation to tMCS occurred in almost 1/5 patients, was more likely in the control group, and was associated with a higher mortality risk. Even with early escalation (<1 h), patients escalated from the control group had the highest mortality, underscoring the need for future trials to define optimal escalation strategies.

Impella CP Reduces Escalation Need in STEMI Cardiogenic ShockTrial shows micro-axial flow pump reduces escalation rates

Common questions

Study Details

Meta-analysis finds systemic lupus erythematosus elevates coronary artery disease risk

People with lupus face higher heart disease risk but genetics show no direct link

Clinical research that matters. Delivered to your inbox.

Impella CP Reduces Escalation Need in STEMI Cardiogenic ShockTrial shows micro-axial flow pump reduces escalation rates

Common questions

Study Details

Meta-analysis finds systemic lupus erythematosus elevates coronary artery disease risk

People with lupus face higher heart disease risk but genetics show no direct link

Clinical research that matters. Delivered to your inbox.

Related in Cardiology

From Other Specialties